Unlocking Nigeria’s Healthcare Value Chain

PVAC, Clinical Trials & the opportunities for a nationalist SMO like Biopharmaal Consulting

Nigeria imports over 70% of its healthcare products, a dependency that leaves 230 million people exposed to supply shocks, price volatility, and preventable deaths. The Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) is the Nigerian government’s bold, structural response: a multi-billion dollar programme to reverse this imbalance, catalyse local manufacturing, and position Nigeria as Africa’s premier hub for health products and clinical research.

What is PVAC?

Inaugurated by President Bola Ahmed Tinubu in October 2023 as a cornerstone of the Renewed Hope Agenda, the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) operates under the Federal Ministry of Health & Social Welfare. Led by National Coordinator Dr. Abdu Mukhtar, PVAC is a time-bound, cross-ministerial initiative designed to unlock billions of dollars in fresh investment into Nigeria’s healthcare ecosystem.

The initiative is built on a simple but powerful logic: Africa bears 25% of the world’s disease burden, yet over 95% of its active pharmaceutical ingredients and 70% of finished pharmaceuticals are imported. The continent’s most populous country (Nigeria) sits at the epicentre of this vulnerability. PVAC aims to flip that equation by 2030, targeting at least 70% local production of essential health products.

$5B – Project pipeline assembled by PVAC as of 2024
$2B – In foreign assembled by PVAC as of 2025
74 Transformative healthcare projects launched or underway

By anchoring itself within the Nigeria Health Sector Renewal Investment Initiative (NHSRII), PVAC does not operate in isolation. It is part of a unified Sector-Wide Approach (SWAp) coordinating government, private sector, development partners, and academia toward shared outcomes.

Mandate, Pillars, and Strategic Goals

PVAC carries an ambitious, multi-faceted mandate that touches every node in Nigeria’s health value chain — from raw ingredient sourcing to patient financing. The initiative is structured around six interconnected work streams:

1. Health Product Manufacturing

Boosting local production of pharmaceuticals, medical devices, diagnostics, vaccines, and APIs to reduce import reliance and strengthen health security.

2. Health Logistics Services

Strengthening supply chains to ensure timely, efficient distribution of health commodities across all 36 states and the FCT.

3. Health Technology Services

Driving digital health innovation, electronic health records, and telehealth platforms to improve access and system efficiency.

4. Health Retail & E-Commerce

Formalising pharmaceutical retail and unlocking digital commerce channels for essential medicines and health products nationwide.

5. Health Provider Facilitation

Attracting investment in hospitals, specialist centres, and the first 500-bed African Medical Centre of Excellence planned for Abuja in 2025.

6. Health Payor Reforms

Restructuring Third-Party Administrators and insurers to expand universal health coverage and reduce out-of-pocket healthcare costs.

“Nigeria is the only country in the world with a population of over 100 million that does not produce the majority of its healthcare products. Our goal is to reverse those numbers and produce 70 percent of health care products locally by 2030.”
— Dr. Abdu Mukhtar, National Coordinator, PVAC

Key early achievements include MoUs with the US Pharmacopeial Convention (USP) to advance manufacturing quality standards and WHO prequalification, a joint venture partnership with Vestergaard Sàrl and a local manufacturing partner, and high-level dialogues with Bayer AG on contraceptive localisation and clinical research in oncology and neglected tropical diseases.
PVAC also launched MediPool, a pooled procurement entity backed by a Presidential Executive Order that offers fiscal incentives to manufacturers and stabilises the supply of essential medicines. The Empower Academy addresses critical human capital gaps by training the next generation of healthcare professionals, researchers, and life sciences entrepreneurs.

Key Clinical Trial Enhancements Under PVAC

One of PVAC’s most strategically significant workstreams is the revitalisation of Nigeria’s clinical research ecosystem. A robust clinical trials sector is not merely about testing new drugs. It is the foundation for pharmaceutical innovation, global research investment, regulatory credibility, and a self-sufficient health system. PVAC has taken deliberate steps to address this long-neglected dimension of the healthcare value chain.

The Nigeria Clinical Trials Consortium

PVAC convened key national institutions to form the Nigeria Clinical Trials Consortium, bringing together NIPRD (National Institute for Pharmaceutical Research and Development), NIMR (Nigerian Institute of Medical Research), NCDC (Nigeria Centre for Disease Control), NHREC (National Health Research Ethics Committee), NHRC, and NICRAT. The Consortium’s purpose is to lay the institutional and infrastructural foundation for a sustainable clinical research ecosystem covering financing, data management, infrastructure development, and human resource capacity.

Why Clinical Trails Matter for PVAC’s Mission

Clinical trial capability directly enables local pharmaceutical manufacturing. Without the ability to conduct Phase I–IV trials domestically, Nigerian manufacturers cannot validate new formulations, achieve global regulatory recognition, or attract multinational partnerships. PVAC views clinical research capacity as a non-negotiable prerequisite for becoming a global health products hub.

Six Pillars of Clinical Trial Enhancement

1. Regulatory Streamlining with NAFDAC: NAFDAC regulates and approves clinical trials under the Federal Ministry of Health. PVAC works with NAFDAC to modernise approval processes, maintain competitive timelines (currently up to three months — faster than China and Brazil), and publish updated CRO eligibility criteria (June 2025). Nigeria’s advancement from below WHO Level 1 in 2016 to Level 3 — the first African country successfully re-benchmarked — provides the regulatory credibility needed to attract global sponsors.
2. 
Ethics Infrastructure via NHREC: The National Health Research Ethics Committee (NHREC) supervises all Institutional Health Research Ethics Committees (IHRECs). PVAC’s alignment ensures that ethical governance for trials is robust, standardised, and internationally recognised — a prerequisite for global sponsor confidence and data acceptability by FDA and EMA.
3. 
Financing Models for Clinical Research: The Clinical Trials Consortium is developing financing frameworks to support domestically funded and co-funded international trials. This mirrors the model that enabled Nigeria’s landmark participation in the first Phase 2 Lassa fever vaccine clinical trial — a CEPI-funded study — in 2024.
4. 
Data Management and Digital Infrastructure
Investment in electronic data capture systems, the Nigeria Clinical Trials Registry (NCTR), and interoperable data platforms ensures trial data meets international standards for WHO, FDA, and EMA review — critical for attracting multinational sponsors and validating locally manufactured products.
5. 
Human Capital via Empower Academy: The Empower Academy delivers training in Good Clinical Practice (GCP), pharmacovigilance, biostatistics, and regulatory affairs — addressing the chronic shortage of skilled clinical research professionals that has long deterred global trial sponsors from choosing Nigerian sites.
6. 
Global Research Partnerships: PVAC’s collaboration with Purpose Africa, USP, and multinational pharmaceutical companies creates channels for technology transfer, co-investment in trial sites, and joint research on diseases with high Nigerian burden — including malaria, Lassa fever, sickle cell disease, and NCDs such as hypertension and oncology.

The strategic logic is clear: a credible, well-resourced clinical trials ecosystem attracts global research investment, generates intellectual property, supports WHO prequalification of locally made products, and reduces Nigeria’s $1 billion-plus annual medical tourism expenditure by building world-class research and treatment capability at home.

The Strategic Role of Site Management Organisations (SMOs) like Biopharmaal Consulting

As PVAC builds Nigeria’s clinical research infrastructure, one category of organisation is positioned to become indispensable: Site Management Organisations (SMOs). As the bridge between clinical trial sponsors, Contract Research Organisations (CROs), and individual trial sites, SMOs provide the operational and administrative backbone that transforms research intent into executed, high-quality trials.

What is an SMO?

An SMO is a specialised entity that provides clinical trial management services to pharmaceutical companies, biotechnology firms, medical device manufacturers, CROs, and clinical investigators. Unlike CROs which manage entire trials at a strategic level, SMOs are site-focused: they optimise the performance of individual clinical sites, ensuring each location within a trial network delivers consistent, compliant, and timely data

SMOs as PVAC Force Multipliers

Within PVAC’s broader vision, SMOs play three interconnected roles that make them structural allies of the initiative:

1. Accelerating Trial Start-Up. One of the most significant barriers to attracting global clinical research to Nigeria has been slow site activation. SMOs, through centralised regulatory management and standardised site preparation protocols, dramatically reduce the time from contract signing to first patient enrolled giving Nigeria a competitive edge against South Africa, Kenya, and Egypt as preferred African trial destinations.
2. Ensuring Data Integrity for Global Submissions. PVAC’s ambition to achieve WHO prequalification for locally manufactured products requires impeccable clinical and bioequivalence data. SMOs provide the monitoring infrastructure (regular site visits), protocol deviation tracking, and query resolution that keeps trial data audit-ready for submission to NAFDAC, FDA, and EMA.
3. Building Durable Research Capacity. Unlike single-trial CRO engagements, SMOs establish permanent site management infrastructure. Each SMO-managed site that completes a trial builds investigator experience, staff capability, and institutional credibility creating a compounding return on PVAC’s investment in clinical research, and directly supporting the goal of retaining Nigerian scientific talent at home.

“For talent to stay in one place, you must provide an enabling environment. We want to make doctors and professionals excited to work here by building the best facilities. By creating the right conditions for employment, our home-grown talent will want to stay here.”
— Dr. Abdu Mukhtar, National Coordinator, PVAC

The SMO Opportunity in Nigeria

Nigeria’s 230 million population with high burdens of malaria, tuberculosis, HIV, Lassa fever, sickle cell disease, hypertension, and cancer represents a uniquely compelling clinical trial landscape. Diverse genetic profiles, high disease prevalence, and an improving regulatory infrastructure create conditions that, with the right site management support, position Nigeria as an irreplaceable partner in global drug development.

SMOs that invest in Nigeria now building networks of GCP-trained investigators, establishing data management systems aligned to PVAC’s digital health strategy, and partnering with the Clinical Trials Consortium are positioning themselves at the frontier of a market that PVAC is actively constructing. The $5 billion project pipeline includes clinical research infrastructure that will require SMO expertise to execute effectively.